Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 19, 2019

Primary Completion Date

July 7, 2023

Study Completion Date

July 7, 2023

Conditions
Proliferative Vitreoretinopathy
Interventions
DRUG

Adrenocorticotropic Hormone

Adrenocorticotropic hormone (ACTH) is a melanocortin peptide hormone that is normally produced in the pituitary gland and acts as a major regulator of adrenal cortex function. It stimulates the adrenal cortex to produce and secrete glucocorticoids. ACTH is available for clinical usage as an injectable gel (H.P. Acthar®).

Trial Locations (1)

21287

Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Johns Hopkins University

OTHER